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Results. The overall survival rates were 100% and 92% at 2 and 5 years, respectively. Five of patients (41.6%) had history of
oligodendrogliomaGII and themedian time to progressionwas 3.5 years. These patients belong to the 55.5% of patients diagnosed
with a GII in this period of time. Two of them, had presented third relapse with median progression-free survival of 2 years. Only
one patient had relapse with primary anaplastic oligodendroglioma with median time to tumor progression of 8 months and
died in 2 years with fotemustine and avastin. This patient had 1p negative.
Conclusion. Based on WHO classiﬁcation and prognostic factor, our combined treatment modality consisting of surgery,
postoperative high-dose RT and chemotherapy based in Temozolamide for patients with anaplastic oligodendroglioma and
oligoastrocytoma was effective. We should ask about other therapeutic strategy in patients with oligodendroglioma GII. We
could think that patients with negative co-deletion higher risk of recurrence. Further studies are needed with more patients and
longer follow-up to verify these results.
http://dx.doi.org/10.1016/j.rpor.2013.03.142
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Background. Treatment approach in meduloblastoma (MB) has changed through the years. The purpose of this study is to assess
the prognostic factors for survival of craniospinal irradiation (CSI) with different modalities of radiotherapy (RT) in MB patients.
Materials and methods. The studywas conducted for patientswithprimaryMB treatedwithCSI fromAugust 1996 throughMay2012.
Inclusion criteria included no prior history of RT and minimum follow up of 6 months for alive patients. Thirty-four patients
(standard risk, N=21; high risk, N=13) met such criteria. Median CSI dose was 36Gy in 20 fractions. The tumor bed received
50–60Gy at 1.5–2Gy/fraction. RT technique used was two dimensional RT (N=11), three dimensional RT (N=15), volumetric
modulated arc therapy (VMAT; N=3), and tomotherapy (N=5). Toxicity was scored using the Radiation Therapy Oncology Group
(RTOG) scoring system. Univariate and multivariate analyses were performed to deﬁne predictors for survival.
Results. The median age at diagnosis was 8 years (range, 2–43) and the median follow-up for alive patients (N=20) 56 months
(range, 9–198). Two and three-year overall survival was 74% and 65%, respectively. Twenty patients underwent complete surgical
resection whereas 14 underwent partial resection. Eleven patients received postoperative chemotherapy (CT). Nine patients had
grade ≥3 hematological toxicity. Overall, 14 patients died. In the univariate analysis, leptomeningeal and cerebrospinal ﬂuid
spread at diagnosis, high risk stage, partial surgery, and CT before RT associated with higher risk of mortality (p<0.05). In the
multivariate analysis, only cerebrospinal ﬂuid spread at diagnosis maintained signiﬁcance (p=0.004).
Conclusion. Several factors related to high risk MB patients, particularly cerebrospinal ﬂuid spread at diagnosis, are associated
with a higher risk of mortality. Further research is necessary to assess a better treatment approach in high risk MB patients in
order to improve the outcome.
http://dx.doi.org/10.1016/j.rpor.2013.03.143
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Objectives. Treatment of high grade gliomas (HGG) have consisted in maximum surgical resection followed by RT concomitant
with temozolomide (TMZ) followed by TMZ for six cycles. This retrospective study evaluates survival for patients with HGG
treated in our institution.
Materials and methods. Data was collected from patient case notes. Statistical analysis was carried out using SPSS package.
Results. Between January 2003 and June 2012, 119 patients with HGG were treated with. They received best supportive care if they
had poor performance status. Histologically, 92% were GM, 4% AA, 4% AOA and 1% negative biopsy. Demographic data were as
follows: 67 males (56%) and 52 females (44%). Median age was 67 years (range 24–91). 4% of the patients had no biopsy because
age was over 80 years old or central tumor location. 86% of the patients had undergone debulking surgery, whereas in 10% just
biopsy was performed. 81 (68%) patients received RT with median dose was 60Gy (range 12–66). Of whom, 88% completed RT. 52
(44%) patients received concurrent radiochemotherapy and 42 (35%) adjuvant TMZ. The major causes to do not receive adjuvant
RT-TMZ were biopsy procedure only or poor performance status (32% of the patients). Median follow-up time was 8 months
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(range 0–49). The median survival time for the whole series was 8.3 months (IC 95%, 6–10) and 38% of patients were still alive at
1 year after diagnosis. There were statistically signiﬁcant differences between those patients who completed RT (13 months (IC
95%, 9–16)) and not completed RT ((4 months (IC 95%, 3–5)), p=0.0001; and between patients treated with RT (5 months (IC 95%,
4–6)) and those receiving combined therapy (15 months (IC 95%, 14–17)), p=0.0001.
Conclusion. Our data conﬁrm that the administration of concurrent RT and TMZ helps to prolong survival for patients with HGG.
http://dx.doi.org/10.1016/j.rpor.2013.03.144
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Material and methods. We analyzed 193 patients treated between 1999 and 2012. The average age 53.2 years, 119 males and 74
females, KS=100:64.2%, KS=90:27.5% and KS=80:8.3%.
Initial symptom. Motor impairment 31.6%, seizure 27.5%, headache 25.9% and other 14.5%.
Surgery. Complete 41.5%, partial excision 43.5% and 15% biopsy. AP:GBM85%, astrocitoma anaplasic AA 13.5%, and other histology
6%.
Treatment. Temozolamine was given as concomitant and adjuvant, 6 or more cycles if tumour remains or progression in 63.7%,
concomitant 20.7% and only adjuvant in 15.6%. Since 2003, carmustine implants were associated +/− RT+/−TMZ at 26.1%.
Results. High overall response rate at the end of treatments: CR 42.3%, PR 21.4%, PE 23.6% and EE 12.6%. A total of 82.8%recurrences
and 17.2% without relapse. Kaplan–Meier average: median overall survival (OS) was 25.8 months (CI 22–29.7), median survival at
16 months (CI 13.4–18.5). OS rate of 61.5%, 32%, 22.6%, 17.5%, 11.7%, 4.1% at 1, 2, 3, 4, 5 and 10 years and respectively. Remain
alive 19.7% (85 months of follow-up). Mean recurrence-free survival (RFS) 11.6 (CI 10–13.2), median 8 months (CI 6.6–9.3). SLR rate
of 30.1%, 10.3%, 2.1%, 0.7%, 0% at 1, 2, 3, 4 and 5 years respectively. In univariate survival analysis for OS the AA histology, age
(<60 years), KS, QT regimen administered (concomitant and adjuvant), and treatment response was signiﬁcant favorable and the
SLR was signiﬁcant in age and KS. On the other hand, was not signiﬁcant the delay on start RT from the surgery and the delay
in the duration of RT in OS or SLR.
Conclusion. Our series reaches a survival rate of 61–11% in 1–5 years, with better outcomes in prognostic factors of OS the age, KS,
histology, QT regimen administrated and the response achieved.
http://dx.doi.org/10.1016/j.rpor.2013.03.145
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Craniospinal irradiation is one of the most challenging radiotherapy techniques. More than one isocenter is needed to cover
the total PTV length, thus creating junction lines and potentially causing over- or under-dosiﬁcation. The aim of this work
is to present our experience with a medulloblastoma case treated with VMAT. The prescribed dose to craniospinal axis was
36Gy (1.8Gy/f) and a boost of 18Gy (1.8Gy/f) to the posterior fossa. The patient was immobilized with head plastic mask and
vacuum bag in supine position. The total PTV length was 79.5 cm. Our VMAT craniospinal technique consisted of three isocenters
located at the center of the head, sixth thoracic vertebra and second lumbar vertebra, respectively. An overlap region was
intentionally created, ranging 2–5 cm, to better control the dose and avoid junction lines. Dailyc Cone Beam CT was programmed
for each isocenter before treatment. For dose comparison purposes, a 3D conformal radiotherapy (3DCRT) plan with 2 isocenters
and daily junction line shift was generated, and literature data with tomotherapy (TX) was used. The PTV dose coverage is
similar, although 3DCRT had worse dose homogeneity. Regarding the organs at risk, medially located organs receive higher
mean dose with 3DCRT, whilst sideways organs receive higher mean dose with both volumetric techniques. The mean dose
with VMAT/TX/3DCRT for different organs is presented, heart: 4.9/11.0/15.3Gy; liver: 6.2/8.0/4.3Gy; lungs: 8.1/6/2.8Gy; kidneys:
6.4/6.5/1.2Gy; thyroids: 9.5/25/27.2Gy; eyes: 10.8/13.3/naGy; larynx: 15.0/28.3/naGy; body 8.1/6.9/10.0Gy. The total treatment time
per fraction is around 30min, 15min for patient positioning, CBCT acquisition and analysis, and 15min for irradiation, lower
than the 45min time reported with tomotherapy for a similar patient. Concluding, VMAT is a safe, fast and accurate technique
for craniospinal irradiation, comparable with tomotherapy, avoiding the junction line problem of 3DCRT.
http://dx.doi.org/10.1016/j.rpor.2013.03.146
